12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
The conversation discusses a user's positive experience with hair regrowth using topical finasteride, minoxidil, and microneedling after 2.5 months, noting initial shedding but improved hair density, especially at the temples, possibly eliminating the need for a hair transplant. The user is satisfied with the current treatment and is hesitant to try the experimental drug RU58841, hoping the current routine will suffice for further improvements.
The user has been using a hair solution with 0.3% finasteride and 5% minoxidil, along with microneedling, but is experiencing more thinning on one side. Suggestions include checking application techniques and ensuring microneedling is not overdone.
A 30-year-old man is considering quitting Finasteride due to sexual side effects, including reduced libido and difficulty reaching orgasm, despite its effectiveness in treating hair loss. He is exploring other factors like relationship issues and potential low testosterone, and is considering getting blood work done.
The conversation discusses an 8.5-month progress of using Minoxidil, Finasteride, and RU58841 for hair loss. People are complimenting the user on the significant improvement in hair thickness.
User reports hair loss improvement with twice-weekly 0.25mg Fin, twice-weekly Min, weekly 0.5mm microneedling, and daily massages. Unconventional regimen contradicts typical advice but may reduce side effects.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.
A 22-year-old male experiencing hair thinning is considering starting finasteride but is concerned about potential side effects and hereditary factors. While waiting to access finasteride, he plans to use pumpkin seed oil, saw palmetto, biotin, and vitamins, and is advised to check blood levels before starting treatment.
Microneedling with needle lengths of 1.5mm to 2.5mm to stimulate hair follicle stem cells for potential hair growth. Using needles longer than 2.5mm is not recommended due to risk of puncturing veins in the scalp. A dermastamp is suggested over a roller.
The conversation discusses starting hair loss treatments and concerns about side effects. Treatments mentioned include Minoxidil, finasteride, and RU58841.
A 28-year-old shared his 2-year hair loss treatment progress using finasteride, minoxidil, dermarolling, and Revita shampoo. He saw significant improvement, especially with minoxidil and dermarolling, and stressed consistency.
A user is treating hair loss with daily 0.5mg Dutasteride, 5mg oral Minoxidil, topical Minoxidil and Dutasteride, 520mg Saw Palmetto, 5mg Biotin, and 0.8mg Folic Acid. They plan to start weekly micro-needling and mix Minoxidil with Tretinoin.
RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.
The conversation discusses hair regrowth using Scandinavian Biolabs products, biotin pills, a dermaroller, rosemary oil, and a silicone head cleaner. The user observes weak hair regrowth and seeks opinions on the results.
The user treated seborrheic dermatitis and hair loss with a routine including sulfate-free tea tree oil shampoo, ketoconazole shampoo, minoxidil foam, microneedling, and supplements like Omega-3 and Vitamin-D. They experienced significant hair shedding initially but saw improvement over a year.
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
The user is considering starting minoxidil and finasteride for hair loss at Norwood 2 or 2.5. Another user suggests consulting a dermatologist and possibly using finasteride to prevent progression and minoxidil for regrowth, with dutasteride as an alternative.
The user discusses their experience with diffuse unpatterned alopecia and acquired progressive hair kinkering, noting improvements with treatments including biotin, pantothenic acid, finasteride, ketoconazole, and zinc pyrithione shampoo. They report thicker, healthier hair and improved scalp condition, attributing success mainly to biotin, pantothenic acid, and finasteride.
Significant hair regrowth was achieved using 1mg finasteride daily, 5% minoxidil nightly, and weekly 1.5mm microneedling, with no side effects. Topical minoxidil and microneedling are recommended for similar results.
A user shared their 4-month hair transplant progress with 3740 grafts, showing before and after pictures. They had a generally good experience, except for the anesthesia part.
User shared 1-year progress on Fin 1 mg, switching to 0.4 mg Dut and oral 1.25 mg Min. Good results with Fin, biotin supplement, and biotin shampoo; trying Dut and oral Min for potential better results.
The conversation discusses the use of a derma roller versus a derma stamp for microneedling to prevent hair loss. The user has been using topical minoxidil for 2 months without results and seeks advice on needle length.
The user reports a stable receding hairline with new hair growth after using 5% minoxidil, 1mg oral finasteride, D-Biotin daily, derma rolling twice a week, and three PRP sessions per month. They plan to update their progress in four months.
The user is experiencing a second hair shedding phase and increased flaking and itching while using minoxidil 5% nightly and microneedling every two weeks, with needle length increasing over time. Other users suggest the hair loss may continue without the use of finasteride.
The conversation is about a user's nearly 4-month hair loss treatment regimen, which includes dutasteride every other day, 0.25ml minoxidil on the hairline once a day, and using a 1.5 mm derma stamp every two weeks. Some responses question the need to start multiple treatments simultaneously, while others comment on the visible improvement and the necessity to continue treatment for sustained results.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
The user is experiencing hair loss and plans to use a treatment protocol including Saw Palmetto Berries, MCT Oil, Zinc, testosterone balancers, L-tyrosine, and L-theanine. They also use a specific dandruff shampoo and are open to non-prescription treatments.
The conversation is about a person starting treatment with RU58841 for hair loss. They are asked to share progress pictures to show if the treatment is effective.
A user shared progress pictures showing improved hair fullness after 75 days using 2.5mg oral minoxidil daily, 1mg oral finasteride every other day, a 1.5mm dermastamp weekly, and daily scalp massages. They report seeing early positive results.